Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EARS
Previous Symbol
CUSIPN/A
Phone41-41-729-7194
Debt
Debt-to-Equity RatioN/A
Current Ratio0.56
Quick Ratio0.56
Price-To-Earnings
Trailing P/E Ratio-0.10
Forward P/E Ratio-1.13
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.36) per share
Price / Book-1.51
Profitability
EPS (Most Recent Fiscal Year)($5.69)
Net Income$-24,800,000.00
Net MarginsN/A
Return on Equity-5,833.92%
Return on Assets-95.92%
Miscellaneous
Employees24
Outstanding Shares6,120,000
Market Cap$3.85 million
OptionableNot Optionable
Auris Medical (NASDAQ:EARS) Frequently Asked Questions
What is Auris Medical's stock symbol?
Auris Medical trades on the NASDAQ under the ticker symbol "EARS."
How were Auris Medical's earnings last quarter?
Auris Medical Holding AG (NASDAQ:EARS) announced its earnings results on Thursday, November, 15th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.03. View Auris Medical's Earnings History.
When is Auris Medical's next earnings date?
What price target have analysts set for EARS?
1 analysts have issued 1 year target prices for Auris Medical's shares. Their predictions range from $2.50 to $2.50. On average, they expect Auris Medical's stock price to reach $2.50 in the next year. This suggests a possible upside of 360.3% from the stock's current price. View Analyst Price Targets for Auris Medical.
What is the consensus analysts' recommendation for Auris Medical?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.
Has Auris Medical been receiving favorable news coverage?
Press coverage about EARS stock has trended very positive on Saturday, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Auris Medical earned a news impact score of 3.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the stock's share price in the next several days.
Are investors shorting Auris Medical?
Auris Medical saw a decrease in short interest in October. As of October 31st, there was short interest totalling 1,176,457 shares, a decrease of 60.0% from the October 15th total of 2,942,457 shares. Based on an average daily trading volume, of 11,134,463 shares, the days-to-cover ratio is presently 0.1 days. Approximately 6.6% of the shares of the company are sold short. View Auris Medical's Current Options Chain.
Who are some of Auris Medical's key competitors?
Some companies that are related to Auris Medical include Relmada Therapeutics (RLMD), Endonovo Therapeutics (ENDV), ERBA Diagnostics (ERBA), DelMar Pharmaceuticals (DMPI), MusclePharm (MSLP), Vital Therapies (VTL), Cyclacel Pharmaceuticals (CYCC), Kazia Therapeutics (KZIA), Uluru (ULUR), Sunwin Stevia International (SUWN), Midatech Pharma (MTP), OHR Pharmaceutical (OHRP), Cellectar Biosciences (CLRB), Regulus Therapeutics (RGLS) and Dare Bioscience (DARE).
Who are Auris Medical's key executives?
Auris Medical's management team includes the folowing people:
- Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 50)
- Mr. Hernan Levett CPA, Chief Financial Officer (Age 42)
- Ms. Michelle Aarts Ph.D., Adviser
- Mr. Giles Hardingham Ph.D., Adviser
- Mr. Jean Martinez Ph.D., Adviser
How do I buy shares of Auris Medical?
Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Auris Medical's stock price today?
One share of EARS stock can currently be purchased for approximately $0.5431.
How big of a company is Auris Medical?
Auris Medical has a market capitalization of $3.85 million. The biotechnology company earns $-24,800,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis. Auris Medical employs 24 workers across the globe.
What is Auris Medical's official website?
How can I contact Auris Medical?
Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]
MarketBeat Community Rating for Auris Medical (NASDAQ EARS)
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
